Angola vs Iran: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Angola
54.0%
in 2025
Iran
54.0%
in 2025
Angola rank
151st
Iran rank
151st
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Angola
- Iran
How they compare
Angola currently reports 54.0% against 54.0% in Iran, a difference of 0.0%.
The two have swapped places 2 times across 18 shared years of data; in 2008 it was Iran ahead.
Angola ranks 151st and Iran ranks 151st of 192 countries.
Angola has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Angola | Iran | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | β |
| 2010s | 35.9% | 0.0% | 35.9% | Angola |
| 2020s | 53.3% | 9.0% | 44.3% | Angola |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Angola or Iran?
- Angola, at 54.0% against 54.0% in Iran as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Angola and Iran?
- 0.0%, with Angola ahead.
- How many years of comparable data are there for Angola and Iran?
- 18 years are reported by both, from 2008 to 2025.
- How do Angola and Iran rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Angola ranks 151st and Iran ranks 151st of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.